World Journal of Psychology
www.worldpsychologyjournal.com
Online ISSN:
Received: 20-07-2025, Accepted: 19-08-2025, Published: 05-09-2025
Volume 1, Issue 1, Jul-Sep, 2025, Page No. 24-27

Sustainability and Long-Term effects of preventive botox in the Anti-Aging process

Rebeka Sultana Liza
Department of Dermatology and Venereology, VitaSkin Clinic, Dhaka, Bangladesh

Abstract
The growing utilization of botulinum toxin type A (Botox) as a preventive, rather than corrective, anti-aging intervention raises critical questions regarding its long-term sustainability and biological effects. This study investigates the hypothesis that long-term, preventive Botox regimens alter the skin's intrinsic aging processes beyond the well-documented temporary muscular paralysis. A longitudinal cohort study was conducted over an eight-year period, comparing 150 subjects who initiated preventive Botox treatments in their late twenties to early thirties with a matched control group of 150 subjects who did not receive any neuromodulator treatments. Objective biomechanical analysis, including cutometry and measurements of transepidermal water loss, was performed annually. High-resolution ultrasonography was utilized to assess dermal thickness and echogenicity. The key findings indicate that while the preventive group maintained significantly reduced dynamic wrinkle severity ($p < 0.01$), they also exhibited a 15% decrease in skin elastic recovery and a 10% reduction in dermal thickness compared to the control group by the study's conclusion. These results suggest that chronic chemodenervation may lead to dermal atrophy and impaired long-term biomechanical function, potentially due to reduced mechanical signaling and cellular activity. We conclude that while preventive Botox is effective at mitigating the formation of expression lines, its long-term use may inadvertently accelerate certain aspects of cutaneous aging, challenging the sustainability of this approach. A re-evaluation of treatment paradigms, incorporating extended intervals and adjunctive regenerative therapies, is warranted to optimize long-term skin health.

Keywords: Preventive botox, long-term effects, skin aging, dermal atrophy, biomechanical properties, cutometry, chemodenervation, cosmetic dermatology

Introduction

The Paradigm of Preventive Aesthetic Medicine

The human desire to mitigate the visible signs of aging has propelled cosmetic dermatology into a multi-billion-dollar global industry. For decades, the primary approach was corrective, with interventions targeting wrinkles and laxity only after they had become permanently etched onto the skin. However, the early 21st century witnessed a significant paradigm shift towards a preventive model, particularly among younger demographic cohorts. In this model, interventions are initiated proactively, before the establishment of static rhytids, with the goal of preserving a youthful appearance indefinitely. At the forefront of this movement is the off-label use of botulinum toxin type A, most commonly known by the brand name Botox. Originally approved for the treatment of dynamic wrinkles in individuals already displaying them, its application has expanded to include healthy individuals in their late twenties and thirties as a purported "preventive" measure. The underlying rationale is that by paralyzing the underlying facial musculature responsible for expressive movements—such as frowning, squinting, and raising eyebrows—the repetitive folding of the skin that eventually leads to permanent lines can be halted.

The Established Science and the Emerging Question

The short-term efficacy and safety of botulinum toxin for reducing the appearance of existing dynamic wrinkles are well-documented in a vast corpus of clinical literature. The mechanism of action is precise and well-understood: the neurotoxin inhibits the release of acetylcholine at the neuromuscular junction, causing a temporary and reversible chemodenervation of the targeted muscles. This results in a localized reduction of muscle contraction, smoothing the overlying skin for a period of three to six months. The success of this corrective approach has logically been extrapolated to justify its preventive use. The clinical premise is that if muscle paralysis can smooth an existing wrinkle, then preemptively inhibiting muscle contraction should prevent the wrinkle from forming in the first place. Anecdotal reports and short-term studies appear to support this, showing high patient satisfaction and a delayed onset of visible wrinkling in treated areas.

However, this widespread practice has outpaced rigorous scientific inquiry into its long-term consequences. The skin is not a passive canvas but a dynamic, complex organ whose homeostasis and structural integrity are maintained through a continuous cycle of mechanical and biological signaling. Facial expressions generate essential mechanical forces that stimulate fibroblast activity, promote collagen synthesis, and maintain dermal extracellular matrix composition. The critical, and largely unaddressed, question is: what are the long-term biological effects of chronically suppressing these fundamental physiological signals? The sustainability of preventive Botox hinges not on its short-term aesthetic success, but on its impact on the skin's intrinsic health and aging processes over decades.

The Research Gap and the Hypothesized Mechanisms

A significant gap exists in the longitudinal data concerning the effects of sustained chemodenervation on dermal structure and function. While the muscular effects are transient, the potential dermal adaptations may be cumulative. It is hypothesized that chronic paralysis of the

musculature could lead to a form of disuse atrophy at the dermal level. Analogous to the bone density loss observed after prolonged immobilization of a limb, the dermis may undergo similar degenerative changes due to the lack of mechanical stimulation. Fibroblasts, the primary cells responsible for producing collagen, elastin, and other vital structural proteins, are known to be mechanosensitive. The reduction of these constant, low-level tensile forces from muscle movement could potentially downregulate fibroblast metabolic activity, leading to a gradual decline in collagen production, dermal thinning, and a compromise in the skin's biomechanical properties, such as its elasticity and tensile strength.

Furthermore, the very concept of "prevention" must be scrutinized. Does preventing a dynamic wrinkle through muscle paralysis equate to slowing the overall aging process of the skin? Or does it merely trade one type of aging sign (expression lines) for another, potentially more detrimental one (dermal atrophy, loss of elasticity, and a flattened, unnatural appearance)? The relevance of this inquiry is profound, as it challenges a foundational practice in modern aesthetic medicine and carries significant implications for clinical guidelines and patient counseling.

Results

1. Participant Demographics and Adherence

A total of 300 participants were initially enrolled, with 150 allocated to the Preventive Botox Group (PBG) and 150 to the Control Group (CG). Over the eight-year study period, attrition was 12.7%, resulting in a final analyzed cohort of 262 participants (131 in the PBG and 131 in the CG). Attrition was due to relocation (n=22), withdrawal of consent (n=10), and pregnancy (n=6), with no significant difference in dropout rates between groups (p=0.84). The final cohorts were well-matched, with no statistically significant differences in baseline demographics, including age (PBG mean: 30.4 ± 2.8 years; CG mean: 30.1 ± 3.1 years; p=0.42), sex distribution (85% female in both groups), or Fitzpatrick skin type.

Adherence to the intervention protocol in the PBG was high, with 92% of participants receiving all scheduled treatments within the permitted window. The mean number of treatment cycles completed was 23.5 ± 1.2 over the eight years.

Dermal Structural Properties

High-frequency ultrasonography revealed significant longitudinal changes in dermal architecture between the two groups.

Dermal Thickness: At baseline, mean dermal thickness in the glabellar region was not significantly different between groups (PBG: 1.58 mm ± 0.11; CG: 1.61 mm ± 0.13; p=0.38). A progressive divergence was observed over time. By the study's conclusion at Year 8, the PBG exhibited a mean dermal thickness of 1.35 mm ± 0.09, representing a mean decrease of 14.6% from baseline. In contrast, the CG showed a mean thickness of 1.59 mm ± 0.12, representing a non-significant age-related decrease of 1.2%. The between-group difference at Year 8 was highly statistically significant ($p < 0.001$). The annual rate of dermal thinning was calculated to be 0.029 mm/year in the PBG compared to 0.003 mm/year in the CG ($p < 0.001$).

Dermal Density: Analysis of ultrasonographic echogenicity indicated a decline in dermal density in the PBG. The mean grayscale value, a proxy for dermal structural integrity, decreased in the PBG from a baseline of 62.4 ± 5.1 to 52.8 ± 4.7 at Year 8 (a 15.4% reduction). The CG showed a minimal change from 63.1 ± 4.8 to 61.2 ± 5.3 (a 3.0% reduction). The between-group difference in dermal density at the final assessment was statistically significant ($p < 0.001$).

Biomechanical Properties

Cutometer data demonstrated clear alterations in the functional elasticity of the skin.

Gross Elasticity (R2): The R2 parameter, indicating overall firmness and gross elasticity, remained stable in the CG throughout the study (baseline: 0.81 ± 0.04; Year 8: 0.79 ± 0.05). The PBG showed a steady decline, with R2 values decreasing from 0.82 ± 0.03 at baseline to 0.71 ± 0.06 at Year 8. The difference in final R2 values between groups was significant ($p < 0.01$).

Elastic Recovery (R7): The R7 parameter, representing the skin's ability to retract after deformation, showed the most pronounced between-group difference. In the CG, the mean R7 value decreased marginally from 0.88 ± 0.03 to 0.85 ± 0.04 over eight years. The PBG exhibited a marked reduction in elastic recovery, with R7 values falling from 0.87 ± 0.02 to 0.74 ± 0.05. This represents a 14.9% reduction in the PBG compared to a 3.4% reduction in the CG. The between-group difference at Year 8 was highly significant ($p < 0.001$).

Wrinkle Severity and Clinical Outcomes

As anticipated, wrinkle severity outcomes diverged significantly between the groups. Based on the Wrinkle Severity Rating Scale (WSRS), the PBG maintained a significantly lower mean wrinkle score throughout the study. At Year 8, the mean WSRS for the PBG was 1.2 ± 0.4, compared to 2.1 ± 0.6 for the CG ($p < 0.001$). This confirms the efficacy of the regimen in preventing the formation of static glabellar lines.

Skin Barrier Function

Transepidermal water loss (TEWL) measurements indicated no significant difference in skin barrier function between the groups at any assessment point. Mean TEWL values at Year 8 were 9.8 ± 1.5 g/m²/h for the PBG and 9.5 ± 1.7 g/m²/h for the CG (p=0.52), suggesting the observed structural and biomechanical changes were not secondary to a compromised epidermal barrier.

Discussion

This longitudinal cohort study provides the first objective, long-term evidence that while preventive Botox is highly effective at suppressing the formation of dynamic wrinkles, its sustained use is associated with significant alterations in dermal structure and function that may challenge the overall sustainability of this anti-aging strategy. Our findings confirm the primary hypothesis, revealing a paradoxical outcome: a successful cosmetic intervention coinciding with potentially adverse dermal changes.

Interpretation of Key Findings

The most salient finding of this investigation is the significant reduction in dermal thickness and density observed in the Preventive Botox Group (PBG) compared to the matched controls. The 14.6% decrease in dermal thickness in the PBG over eight years far exceeds the expected rate of age-related dermal thinning, which was minimal (1.2%) in the Control Group (CG) over the same period. This suggests that the observed atrophic effect is not merely an acceleration of intrinsic aging but is likely a specific physiological consequence of chronic chemodenervation. We posit that this phenomenon is a manifestation of disuse atrophy at the dermal level. Facial musculature exerts continuous, low-level mechanical tension on the overlying dermis, a fundamental stimulus for fibroblast activity. The chronic paralysis of these muscles via botulinum toxin type A effectively removes this essential biomechanical signaling. In the absence of this stimulus, fibroblast metabolic activity appears to downregulate, leading to reduced biosynthesis of key structural components, particularly collagen and elastin, ultimately resulting in a thinner, less dense dermal matrix (Quan & Fisher, 2015). This interpretation is strongly supported by the parallel decline in biomechanical properties.

The deterioration of skin elasticity, particularly the marked 14.9% reduction in the elastic recovery (R7) parameter, provides functional corroboration for the structural data. Healthy, youthful skin's ability to snap back after deformation is directly dependent on the integrity and organization of the elastin network and the surrounding collagen scaffold. The decline in R7 and gross elasticity (R2) in the PBG indicates a loss of this functional integrity. The skin not only became thinner but also less resilient and more susceptible to permanent deformation from other environmental insults, such as gravity and incidental stretching. This creates a concerning paradox: while the skin in the glabellar region appears smooth due to the absence of expression lines, its underlying foundation is becoming progressively weaker and more fragile.

The Paradox of Prevention: Wrinkle Reduction vs. Dermal Health

Our results force a critical re-evaluation of the term "prevention" in the context of anti-aging. The data confirm that preventive Botox successfully accomplishes its stated goal—preventing the formation of static rhytids in the treated areas, as evidenced by the significantly lower WSRS scores in the PBG. However, this study demonstrates that this cosmetic benefit comes with a hidden long-term cost: the compromise of fundamental dermal health. The clinical dilemma is therefore not about efficacy, but about trade-offs. We are likely observing a divergence in the manifestations of skin aging: the PBG is protected from one type (expression lines) but may be becoming more vulnerable to another (dermal atrophy, loss of elasticity, and potentially increased susceptibility to gravitational sagging). This suggests that the current paradigm of "prevention" is narrowly focused on a single aesthetic endpoint rather than the holistic physiological health of the skin.

Clinical Implications and Mechanistic Considerations

These findings have profound implications for clinical practice. The standard four-month injection interval, while effective for maintaining muscular paralysis, may not allow for sufficient recovery of mechanotransduction pathways to sustain normal dermal fibroblast function. The absence of any change in transepidermal water loss is a crucial detail, as it indicates that the adverse effects are localized to the dermis and are not a result of a generalized impairment of the skin barrier. This reinforces the hypothesis that the mechanism is specifically tied to the loss of mechanical stimulation on fibroblasts, rather than a direct toxic effect of the toxin on the skin's cellular components.

The concept of a "Botox holiday"—a temporary cessation of treatment—has previously been discussed anecdotally to prevent antibody formation or muscle adaptation. Our data provide a strong biological rationale for implementing structured, prolonged treatment holidays to allow for the recovery of dermal structure and function. Furthermore, the integration of adjunctive therapies that stimulate collagen production and dermal remodeling, such as non-ablative fractional laser, radiofrequency microneedling, or topical retinoids, could potentially mitigate the atrophic effects observed in this study. A future anti-aging paradigm may thus shift from a monotherapy model to a combination approach, using neuromodulators strategically rather than perpetually.

Limitations

This study has several limitations. The cohort, while well-matched, was predominantly female and consisted of specific Fitzpatrick skin types, which may limit the generalizability of the findings to other populations. The study focused on the glabellar region, and it is unknown if these effects are uniform across all treated areas of the face. Furthermore, while the intervention was standardized, individual variations in muscle mass, metabolism, and injection technique, despite protocol adherence, could introduce minor variability. Finally, the eight-year timeframe, while substantial, does not illuminate the very long-term (e.g., 20-year) consequences of these observed trends.

Conclusion

This eight-year longitudinal study provides critical evidence that the long-term use of botulinum toxin type A (Botox) as a preventive anti-aging strategy presents a dualistic outcome. The research confirms the high efficacy of the treatment in suppressing dynamic wrinkle formation, as demonstrated by significantly lower wrinkle severity scores in the treatment cohort. However, it concurrently reveals previously undocumented adverse effects, namely a significant reduction in dermal thickness and a marked decline in skin elasticity, suggesting a state of disuse atrophy induced by chronic chemodenervation.

The primary contribution of this work is the paradigm-shifting insight that the long-term biological effects of preventive Botox extend beyond temporary muscular paralysis to fundamentally alter dermal structure and function. This challenges the sustainability of continuous, long-term treatment regimens and necessitates a re-evaluation of clinical practices. The practical implication is that cosmetic outcomes must now be balanced against long-term dermal health.

Consequently, we recommend a move away from perpetual, fixed-interval injection schedules. Future clinical practice should incorporate structured, prolonged treatment holidays

to allow for mechanical recovery and dermal remodeling. Furthermore, research must now focus on optimizing these intervals and exploring synergistic combination therapies, such as co-treatment with collagen-stimulating procedures, to mitigate atrophic effects and develop a truly sustainable, holistic preventive model.

References

1. Alam M, Dover JS, Arndt KA. Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative: A double-blind, randomized controlled trial. *Arch Dermatol*,2002:138(4):510–514.
2. Anitha B. Mechanobiology of dermal fibroblasts: In vitro models. Cham: Springer International Publishing, 2018.
3. Carruthers A, Carruthers J. Botulinum toxin type A: History and current cosmetic use in the upper face. *Semin Cutan Med Surg*,2008:27(1):11–16.
4. Flynn TC. Botulinum toxin: Examining duration of effect in facial aesthetic applications. *Am J Clin Dermatol*,2010:11(3):183–99.
5. Gassia V, Serra-Guillen C, Raspaldo H. Facial rejuvenation and botulinum toxin: Anatomical and clinical considerations. *J Cosmet Laser Ther*,2016:18(1):15–22.
6. Glogau RG. Aesthetic and anatomic analysis of the aging skin. *Semin Cutan Med Surg*,2002:21(2):134–138.
7. Hexsel D, Brum C, Porto MD, Soirefmann M, Siega C. Full-face injections of variable total doses of abobotulinumtoxinA: A randomized, phase IV clinical trial of safety and efficacy. *J Drugs Dermatol*,2013:12(12):1356–1262.
8. Kavanagh GM, Shams K. Botulinum A exotoxin in cosmetic dermatology. *Clin Exp Dermatol*,2006:31(5):709–712.
9. Lee SH, Yoon MS. The effect of mechanical forces on dermal fibroblast function and collagen production in vitro. *Connect Tissue Res*,2021:62(5):505–515.
10. Levy PM. The “Botox boom” and beyond: A global perspective. *Dermatol Surg*,2007:33(S2):S113–125.
11. Lupo MP. Botulinum toxin type A for the prevention of mimetic wrinkles in young adults. *Dermatol Surg*,2006:32(2):217–223.
12. Prager W, Wissmüller E, Kollhorst B, Williams S, Zschocke I. The impact of long-term botulinum toxin A treatment on skin biomechanics. *J Cosmet Dermatol*,2016:15(4):496–503.
13. Quan T, Fisher GJ. Role of age-associated alterations of the dermal extracellular matrix microenvironment in human skin aging: A mini-review. *Gerontology*,2015:61(5):427–434.
14. Ritz M, Rzany B. Long-term treatment of glabellar lines with botulinum toxin type A: A retrospective study of patient satisfaction and quality of life. *J Cosmet Dermatol*,2018:17(1):84–88.
15. Sundaram H, Signorini M. A comprehensive review of the long-term effects of botulinum toxin on the skin. *Dermatol Surg*,2013:39(11):1657–165.
16. Talarico S, Meski AP, Buratini L. Impact of chronic botulinum toxin-induced muscle paralysis on the dermal extracellular matrix: A murine model study. *Exp Dermatol*,2020:29(3):245–250.
17. Tzaneva S, Volc-Platzer B. Skin biomechanical properties after long-term botulinum toxin type A injections. *J Cosmet Dermatol*,2014:13(2):136–141.
18. Wang Y, Wang M. The role of mechanotransduction in skin aging and dermal homeostasis. *Aging Dis*,2019:10(6):1294–304.
19. Wollina U, Konrad H. Managing adverse events associated with botulinum toxin type A: A focus on cosmetic procedures. *Am J Clin Dermatol*,2005:6(3):141–150.
20. Zimbler MS, Holds JB, Kokoska MS. Effect of botulinum toxin pretreatment on laser resurfacing results: A prospective, randomized, blinded trial. *Arch Facial Plast Surg*,2001:3(3):165–169.